¿Qué debemos conocer de los inhibidores de bomba protones, para su uso en las unidades de dolor?

• Autores: J. A. García García
• Localización: Revista de la Sociedad Española del Dolor (SED), ISSN 1134-8046, Vol. 14, Nº. 7, 2007, págs. 501-510
• Idioma: español
• Títulos paralelos:
  • What need to know the Proton Pump Inhibitors to use in the chronic pain clinic?
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Los inhibidores de la bomba de protones (IBP) son fármacos útiles para el control de la patología asociada con la acidez gástrica, patología con una alta prevalencia dentro de la población general. En las Unidades de dolor tratamos pacientes con pluripatología y polimedicados, entre ellas patologías asociadas con la acidez gástrica. Así como también utilizamos fármacos como AINES, glucocorticoides, bifosfonatos... que pueden reactivar, empeorar la patología ligada a la acidez. El conocimiento de los aspectos farmacológicos de los IBP, tanto farmacocinéticos como farmacodinámicos, es necesario y preciso para poder elegir el más adecuado para nuestros pacientes con pluripatologia y polimedicados evitando las posibles interacciones farmacológicas que podrían afectar al estado de salud de nuestros pacientes.

  • English

    Protón Pump Inhibitors (PPIs) have shown their usefulness in the treatment of acid-related disorders, highly prevalent in normal population. Pain units are used to treating patients with a wide range of diseases, including acid related-disorders, who are also being prescribed many different drugs, like NSAIDs, corticosteroids or biphosponates, which may reactívate or even worsen acid-related disorders. Knowledge of the pharmacological aspects of PPIs, both their pharmacokinetics and pharmacodynamics, is needed to properly choose the one which fits most to our multi-pathologic, multi-treated patients, in order to avoid possible pharmacological interactions than could endanger their health condition.

• Referencias bibliográficas
  • Skoczylas, T. (2003). Significant enhancement of gastric mucin content after rabeprazole administratioin: Its potencial clinical significance...
  • Jaworski, T. (2005). Restorative impact of rapebrazole on gstric mucus and mucin production impairment during naproxen administration: its...
  • Pantoflickova, D, Dorta, G, Ravic, M, Jornod, P, Blum, AL. (2003). Acid inhibition on the first day of dosing: comparison of four protón pump...
  • Barnett, J.L, Robinson, M. (2001). Optimizing Acid-Suppresion Therapy. Managed Care. 10. 17-21
  • Kromer, W, Kruger, U, Huber, R, Hartmann, M, Steinijans, vW. (1998). Differences in pH-dependent activation rates of substituted benzimidazoles...
  • Willians, MP, Sercombe, J, Hamilton, MI, Pounder, RE. (1998). A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole...
  • Robinson, M, Horn, J. (2003). Clinical Pharmacology of Protón Pump Inhibitors: What the Practising Physician Needs to Know. Drugs. 63. 2739-2754
  • Wilder-Smith, C, Claar-Nilson, c, Hasselgren, G. (2001). Esomeprazole mg provides faster and more effective acid control than rabeprazole...
  • Warrington, S, Baisley, K, Boyce, M. (2002). Effeets of rabeprazole, 20 mg, or esomperazole 20 mg, on 24 h. intragastric pH and serum gastan...
  • Futura, T, Ohashi, K, Kosuge, K. (1999). CYP2C19 genotype status and effect of omeprazole on intragastriaca pH in humans. Clin Pharmacol Ther....
  • Saitoh, t, Fukushima, Y, Otsuka, H. (2002). Effects of rabeprazole,lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers....
  • Sachs, G. (2001). Improving on PPI-based therapy of GORD. Eur j Gastroenterol Hepatol. 13. 35-41
  • Besancon, M, Simón, A, Sachs, G. (1997). Sites of reaction of gastric H, K-ATPase with extracytoplasmic thiolre-agents. J Biol Chem. 5. 22438
  • Kromer, W. (2001). Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired Sh reactions impact of...
  • Baisley, KJ, Warrington, SJ, Tejura, B. (2002). Rabeprazole 20 mg compared with esomeprazole 40 mg in the control intragastric pH in healthy...
  • Touw, DJ. (1997). Clinical Implications of genetic plymorphisms and drug interaccions mediated by cytrocromo P 450 enzymes. Drug metabol Drug...
  • Ishizak, T, Horai, Y. (1999). Review article cytochrome P45= and the metabolism of protón pump inhibitors: emphasis on rabeprazole. Aliment...
  • Goldstein, JA. (2001). Clinical relevance of genetic polymorhisms in the human CYP2C subfamily. Br j Clin Pharmacol. 52. 349
  • Anderson, T, Rohss, K, Bredberge. (2001). Pharmacokineics and pharmacodynamics of esomeprazole: The (s)- isomer of omeprazole. Aliment Pharmacol...
  • Futura, T, Kyoichi, O, Kosuge, K. (1999). CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther....
  • Horai, Y, Kimura, m, Furvie, H. (2001). Phamiacodynamic effect and Kinect disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment...
  • Humphries, TJ, Merritt, GJ. (1999). Review arricie: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther....
  • Hansten, P, Horne, J. (2003). The top 100 drug interactions: a guide to patients managemente. H andH Publications. Edmonds(WA).
  • Ahmad, S. (1991). Omeprazole-warfarin interaction (letter). South Med J. 84. 674
  • Ushima, H, Echizen, H, Ñachi, S. (1995). Dose-dependent inhibition of CYP3A4 activity by clarithromycin durn Helicobacter pylori eradication...
  • Homma, m, itagki, F, Yuzawa, K. (2002). Effects of lansoprazole and rabeprazole on tracrolimus blood concentrations: case of a renal transplant...
  • Tróger, U, Stótzel, B, Martens-Lobenhoffer, J. (2002). Drug points: sever myalgia from an interaction between treatments with pantoprazole...
  • Anderson, T, Hassan-Alin, m, Hasselgren, G. (2001). Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet....
  • Tybring, G, Bottiger, Y, Widen, J. (1997). Enantioselective hydroxylation of omeprazole catalyzed by CYP 2CPY19 IN Swedish white subjects....
  • Caro, JJ, Salas, M, Ward, A. (2001). Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibors...
  • Richter, JE, Kahrilas, PJ, Johanson, J. (2001). Efficay and safety of esomeprazole compared with omeprazole in GERD patients with erosive...
  • Howden, C, Bllard, D, Robieson, W. (2002). Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment...
  • Castell, DO, Kahrilas, PJ, Richter, JE. (2002). Esomeprazole (40mg) compared with lansoprazole 30mg in the treatment of erosive esophagitis....
  • Lai, KC, Lam, SK, Chu, KM. (2002). Lansoprazole for the prevention of recurrences of ulcer complications from long-term low dosi aspirine...
  • Sheiman, JM, Yeomans, ND, Talley, N J. (2006). Prevención de úlceras con esomeprazol en pacientes de riesgo bajo tratamiento con AINE no selectivo...
  • Landes, BD, Petite, JP, Fluovat, B. (1995). Clinical Pharmacokinetics of lansoprazole. Clin Pharmoacokinet. 28. 458
  • Bate, CM, Griffin, SM, Keeling, PWN. (1996). Reflux sympton relief with omeprazole in patients without unequivocal esophagitis. Aliment Pharmacol...
  • Venables, TL, Newland, RD, Patel, AC. (1997). Maintenance treatment for gastroesophageal reflux desease: a placebo-controlled evaluation of...
  • Richter, JE, Kovacs, TO, Greski-Rose, PA. (1999). Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment...
  • Talley, N J, Lauritsen, K, Tunturi-Hihnala, H. (2001). Esomeprazole 20 mg maintains sympton control in endoscopy negative gastroesopheageal...
  • Byzter, P, Blum, AL, de Herdt, D. (2003). Fast and complete control of heraburn in on demand rebeprazole maintenance therapy in patients with...
  • HolbrooK,, AM, Pereira, JA, Labiris, R. (2005). Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 165....
  • Thojodleifsson, Bm, Beker, JA. (2000). Rabeprazole versus Omeprazole in Preventing relapse of erovise or ulcerative gastroesophageal reflux...
  • Thijssen, HH, Flinois, JP, Beaune, PH. (2000). Cytochrome P4502c9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions...
  • Caos, A, Moskovitz, M. (2000). Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal...